This proposal addresses the Group D Provocative Question (PQD5): Since current methods to predict the efficacy or toxicity of new drug candidates in humans are often inaccurate, can we develop new methods to test potential therapeutic agents that yield better predictions of response? We will address critical shortcomings in predicting therapeutic responses to anticipate tumor recurrence and improve patient outcome, which is usually based on tumor heterogeneity. We will accomplish this goal by developing and applying a novel single-cell response measuring technology, termed a High-Throughput Screening Live Cell Interferometer (HTS-LCI), to quantify single-cell biomass changes temporally, before and during drug exposure. With 10,000s of time-dependent biomass profiles, we will rapidly characterize a tumor's heterogeneous kinetic response to therapy in order to provide a quantitative statistical classifier. Our proposal is transformative with broad implications for all types of cancer, but here we focus on metastatic melanoma (mainly stage III-IV) because 1) it is a common cancer with increasing incidence, 2) is often rapidly fatal, and 3) much is known about targeted therapy and resistance. Specifically, MAPK pathway-activating BRAF serine/threonine kinase mutations are present in ~50% of melanomas. Importantly, well-characterized BRAF-inhibitor (BRAFi) sensitive and resistant cell lines and fresh patient melanoma samples are readily available for proof-of-principle preclinical studies. Approaches in personalized medicine rely on static biomarker, genomic, and epigenetic parameters to refine therapy choice and predict prognosis, but they all fail to incorporate therapeutic response, which is a critical omission. Validated, individualized tumor cell response profiling could have enormous impact on therapeutic efficacy, rapid cancer diagnosis, prognosis, and prediction of tumor recurrence. To reach this goal we propose a new approach with three innovative components that include 1) engineering the HTS- LCI to quantify tumor cell biomass changes in response therapeutic agents, in real time;2) using paired BRAFi sensitive and resistant patient-derived metastatic melanoma cell lines that have been extensively characterized for genomic, epigenomic, and expression profiling by our collaborators;and 3) utilizing our immediate access to de-identified patient samples through collaboration with Jonsson Comprehensive Cancer Center clinicians and their ongoing early phase clinical trials.
The Specific Aims of our proposal are:
Aim 1 : To generate a BRAFi sensitive and resistant paired melanoma cell line statistical classifier.
Aim 2 : To engineer the HTS-LCI for multi-drug growth rate profiling in a 36-well plate format.
Aim 3 : To evaluate the HTS-LCI for rapid response detection of BRAFi sensitive and resistant lines.
Aim 4 : To apply the HTS-LCI platform for biomass profiling of fresh melanoma patient samples.

Public Health Relevance

The clinical course and outcome for melanoma patients remains variable despite therapies that are usually guided by a combination of clinical assessments, including tumor subtype, clinical grade and stage, and activating mutations of the MAPK cell growth and signaling pathway, including BRAF (~50% of cases) and N-RAS (~10% of cases) protein kinases. Real-time biomass profiling of live tumor cell growth and regression responses to therapeutic agents with an incubator-based High-Throughput Screening Live Cell Interferometry (HTS-LCI) is a new and reproducible biophysical quantifier that promises to rapidly (within hours) identify optimal therapeutic agents and sub-classify tumors based on therapeutic response in order to improve predictions of patient prognosis and tumor recurrence.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (J1))
Program Officer
Sorg, Brian S
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Schools of Medicine
Los Angeles
United States
Zip Code
TeSlaa, Tara; Setoguchi, Kiyoko; Teitell, Michael A (2016) Mitochondria in human pluripotent stem cell apoptosis. Semin Cell Dev Biol 52:76-83
Wu, Ting-Hsiang; Sagullo, Enrico; Case, Dana et al. (2016) Mitochondrial Transfer by Photothermal Nanoblade Restores Metabolite Profile in Mammalian Cells. Cell Metab 23:921-9
Patananan, Alexander N; Wu, Ting-Hsiang; Chiou, Pei-Yu et al. (2016) Modifying the Mitochondrial Genome. Cell Metab 23:785-96
TeSlaa, Tara; Chaikovsky, Andrea C; Lipchina, Inna et al. (2016) ?-Ketoglutarate Accelerates the Initial Differentiation of Primed Human Pluripotent Stem Cells. Cell Metab 24:485-493
Setoguchi, Kiyoko; TeSlaa, Tara; Koehler, Carla M et al. (2016) P53 Regulates Rapid Apoptosis in Human Pluripotent Stem Cells. J Mol Biol 428:1465-75
Lin, Ming-Yu; Wu, Yi-Chien; Lee, Ji-Ann et al. (2016) Intracellular Delivery by Shape Anisotropic Magnetic Particle-Induced Cell Membrane Cuts. J Lab Autom 21:548-56
Teslaa, Tara; Teitell, Michael A (2015) Pluripotent stem cell energy metabolism: an update. EMBO J 34:138-53
Kim, Diane N H; Teitell, Michael A; Reed, Jason et al. (2015) Hybrid random walk-linear discriminant analysis method for unwrapping quantitative phase microscopy images of biological samples. J Biomed Opt 20:111211
Walsh, Nicole C; Waters, Lynnea R; Fowler, Jessica A et al. (2015) LKB1 inhibition of NF-?B in B cells prevents T follicular helper cell differentiation and germinal center formation. EMBO Rep 16:753-68
Teitell, Michael A (2015) Adult stem-like cells exclude ""older"" mitochondria. Cell Metab 21:658-9

Showing the most recent 10 out of 16 publications